

Removal of Ticagrelor by Hemoadsorption with the HA380 Cartridge

Taku Furukawa^a Yugeesh R. Lankadeva^{a,b,c} Ian C. Baldwin^d
Pei Chen Connie Ow^a Sally Hood^a Youssef Daali^e Antoine Schneider^f
Laurent A. Decosterd^g Clive N. May^{a,b} Rinaldo Bellomo^{b,d,h,i,j}

^aPreclinical Critical Care Unit, Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Melbourne, VIC, Australia; ^bDepartment of Critical Care, Melbourne Medical School, University of Melbourne, Melbourne, VIC, Australia; ^cDepartment of Anaesthesia, Austin Hospital, Melbourne, VIC, Australia; ^dDepartment of Intensive Care, Austin Hospital, Melbourne, VIC, Australia; ^ePharmacological Investigations Unit, Geneva University Hospital, Geneva, Switzerland; ^fAdult Intensive Care Unit, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; ^gLaboratory of Clinical Pharmacology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland; ^hDepartment of Intensive Care, Royal Melbourne Hospital, Parkville, VIC, Australia; ⁱData Analytics Research and Evaluation Centre, Austin Hospital, Melbourne, VIC, Australia; ^jAustralian and New Zealand Intensive Care Research Centre, Monash University, Melbourne, VIC, Australia

Keywords

Hemoadsorption · HA380 Jafron cartridge · Ticagrelor · Antiplatelet drug

Abstract

Introduction: Hemoadsorption has emerged as a potential intervention for the removal of ticagrelor. We aimed to evaluate the efficacy of the HA380 hemoadsorption cartridge for this purpose. **Methods:** Six healthy adult sheep received 270 mg of ticagrelor via an orogastric tube, followed by hemoadsorption using a HA380 cartridge for a duration of 4 h. The sorbent-based removal ratio, clearance, and mass removal rate were assessed at multiple time points. **Results:** The HA380 cartridge achieved an initial sorbent-based removal ratio of 48.9% (SD 11.8) at 10 min, which declined rapidly to 2.66% (SD 18.5) at 120 min and

0.48% (SD 17.0) at 240 min. Clearance followed a similar trend, starting at 46.1 mL/min (SD 11.4) and decreasing to 0.08 mL/min (SD 16.8) at 240 min. The mass removal rate also dropped significantly over time, from 3.74 ng/min (SD 2.54) at 10 min to near zero at 120 and 240 min. **Conclusion:** HA with the HA380 cartridge can achieve an early 50% adsorption level for ticagrelor. If frequently changed, the HA380 cartridge may serve as a potential option for ticagrelor removal, when clinically indicated.

© 2025 S. Karger AG, Basel

Introduction

Ticagrelor, an antiplatelet drug that acts as a reversible and direct-acting inhibitor of the adenosine diphosphate P2Y₁₂ receptor, is widely prescribed for coronary artery

disease [1]. However, managing ticagrelor in the context of life-threatening bleeding or urgent surgery is extremely challenging due to the lack of drug reversal and/or removal strategies.

Hemoadsorption (HA) is emerging as a potential intervention in these scenarios as indicated by previous studies [2–4]. HA appears to remove ticagrelor from the plasma despite its high protein binding (>99%) leveraging its reversible binding to the P2Y₁₂ receptor [5]. However, current evidence indicates significant variability in drug removal performance across different cartridges used for HA [6].

The HA series (Jafron Biomedical, Zhuhai, China) is a novel group of cartridges designed for HA [7]. While these cartridges have been used for the treatment of drug intoxication [8–11], their efficacy in removing ticagrelor has not been investigated.

Materials and Methods

Experimental Protocol

Six sheep were studied under general anesthesia induced with propofol (4 mg/kg; IV, Feresofol[®], Fresenius Kabi Australia, NSW, Australia) and fentanyl (5 µg/kg; IV, Fentanyl GH, Panpharma, Trittau, Germany) and maintained with sevoflurane (2–4%, Piramal Sevoflurane[®], Piramal Critical Care, Pennsylvania, USA), propofol (4 mg/kg/h; IV), and fentanyl (3 µg/kg/h; IV). Following the induction of general anesthesia, ticagrelor (270 mg, Brilinta, AstraZeneca, Sydney, NSW, Australia) was given via an orogastric tube.

After 75 min, HA was initiated and performed for a total duration of 4 h, using a HA380 cartridge, a dedicated device (TR-525[®], Toray Medical, Tokyo, Japan) and circuit (JCH-55X2-CHDF-2[®], Toray Medical, Tokyo, Japan). The extracorporeal circuits were prepared according to the manufacturer's instructions, as previously described [12]. The blood flow rate was initially set at 30 mL/min and gradually increased over a period of 10 min–120 mL/min. Heparin (Heparin Injection[®]; Pfizer, Sydney, Australia) was given for anticoagulation as a bolus of 3,000 IU followed by a continuous infusion of 2,000 IU/h until the end of experiment.

Blood Samples and Analysis

Blood samples were collected 30, 60, and 75 min after drug administration. After the initiation of HA, additional samples were collected at 10, 30, 60, 120, and 240 min from two different ports located before and after the cartridge. Blood hemoglobin levels were measured

using ABL Systems 625 (Copenhagen, Denmark). Plasma concentrations of ticagrelor were quantified by high-performance liquid chromatography with tandem mass spectrometry [13]. Isotopically labelled internal standards were used for quantification to circumvent the matrix effect variability.

Experimental Measurements

We calculated the sorbent-based removal ratio (RR), clearance (CL), and mass removal rate (V_{rem}) for each time point using the following formulas as previously reported [12]:

$$RR (\%) = (1 - C_{post} / C_{pre}) \times 100$$

$$CL \text{ (mL/min)} = Q_p (C_{pre} - C_{post}) / C_{pre} = Q_p \times RR$$

$$V_{rem} \text{ (mg/min)} = Q_p (C_{pre} - C_{post})$$

C_{pre} and C_{post} represent the drug concentrations in the pre- and post-cartridge samples, respectively. Q_p refers to the effective plasma flow, calculated as the product of the blood flow and (1 minus the hematocrit). Hematocrit was estimated by multiplying the hemoglobin by a factor of three.

Statistical Analysis

Data are presented as means with SDs. Statistical analysis was conducted using GraphPad Prism[®] for Windows, version 10 (GraphPad Software, Boston, MA, USA). Data were subjected to one-way repeated-measures ANOVA with a Greenhouse-Geisser correction applied to the main effect of time. Within-animal comparisons between the 10-min time point and each time point were performed using Dunnett's test. A two-sided p value ≤ 0.05 was considered statistically significant.

Results

Plasma concentrations, the calculated sorbent-based RRs, CLs, and V_{rem} of ticagrelor are shown in Figure 1. The sorbent-based RR of ticagrelor was 48.9% (SD 11.8) at 10 min, decreasing rapidly over time ($P_{time} = 0.0045$, Fig. 1b). By 120 min, the RR had dropped to 2.66% (SD 18.5), and it further declined by 240 min to 0.48% (SD 17.0).

The sorbent-based CL changed proportionally to the RR as Q_p remained relatively stable. CL decreased over time ($P_{time} = 0.0058$), starting at 46.1 mL/min (SD 11.4) and reaching nearly zero by 120 min, with the final CL at 240 min at 0.08 mL/min (SD 16.8, Fig. 1c). The sorbent-based V_{rem} also exhibited a decrease over the




Fig. 1. Effects of HA on ticagrelor. **a** Plasma concentration of ticagrelor. **b** Sorbent-based RR. **c** Sorbent-based CL. **d** V_{rem} . Data are presented as mean and SD. $N = 6$ for all variables. Data were subjected to one-way repeated-measures ANOVA with a Greenhouse-Geisser correction applied to the main effect of “time.” $**p < 0.01$ (post hoc Dunnett’s test) for comparison with the 10 min after initiation of HA. CL, clearance; HA, hemoadsorption; RR, removal ratio; V_{rem} , mass removal rate.

4-h procedure ($P_{time} = 0.0097$), from 3.74 ng/min (SD 2.54) at 10 min to close to zero at 120 and 240 min (Fig. 1d).

Discussion

In anesthetized healthy sheep, the HA380 cartridge initially achieved an RR of approximately 50% for ticagrelor. This RR progressively and rapidly declined, reaching nearly zero by 120 min after HA initiation.

To our knowledge, this study is the first to assess the impact of HA using HA380 cartridges on ticagrelor removal. A previous in vitro study demonstrated substantial removal of ticagrelor using CytoSorb® [2]. However, in vitro adsorption does not reflect in vivo performance [14]. Nonetheless, HA with CytoSorb® may reduce bleeding complications in emergency cardiac surgery requiring

cardiopulmonary bypass [3], and registry studies and clinical trials are currently underway [15, 16]. Moreover, the European Society of Cardiology recommends considering HA in patients on ticagrelor requiring emergency cardiac surgery [17]. Our findings suggest the Jafron HA380 may also have utility in this setting. However, removal of ticagrelor beyond 2 h is low and less than for other drugs, possibly because of its higher protein binding [5, 18, 19]. Desorption remains a concern with these techniques as noted with CytoSorb® cartridges [20]. Thus, our findings indicate that HA380 cartridges can achieve early removal of ticagrelor and suggest that hourly cartridge changes may be desirable. Investigations of this cartridge with frequent changes are now required and justified in clinically relevant scenarios such as during cardiopulmonary bypass.

We acknowledge several limitations. First, we used young, healthy animals, whereas patients requiring urgent ticagrelor removal often present with varying degrees of

organ dysfunction. Second, we did not assess platelet function. However, previous studies have shown that plasma concentrations of ticagrelor closely correlate with inhibition of platelet aggregation [5]. Third, this experiment lacked a blank control. Typically, ticagrelor reaches its peak blood concentration orally within 2–3 h. However, the experiment commenced while the ticagrelor concentration was still potentially increasing, prior to reaching its peak. This timing could have impacted both the adsorber's drug CL capacity and the precision of the calculations. Lastly, higher blood flow rates may achieve greater removal but could not be delivered in a 40 kg sheep.

In summary, HA with the HA380 cartridge achieves 50% adsorption of ticagrelor. This suggests that the HA380 cartridge, combined with frequent change, could serve as a potential option for ticagrelor removal when clinically indicated. Further clinical studies are required and justified in the clinical setting.

Acknowledgments

The authors acknowledge the expert technical assistance of Mr. Tom Vale, Mr. Tony Dornom, and Mr. Quan Nguyen.

Statement of Ethics

All procedures were approved by the Animal Ethics Committee of the Florey Institute of Neuroscience and Mental Health (Approval No. 22-028-FINMH) in accordance with the guidelines of the National Health and Medical Research Council of Australia. The study adhered to the Animal Research: Reporting of In Vivo Experiments (ARRIVE) criteria.

References

- 1 Zwart B, Claessen BEPM, Damman P, Woudstra P, Vink MA, Balder JW, et al. 2023 European Society of Cardiology guidelines for the management of acute coronary syndromes: statement of endorsement by the NVVC. *Neth Hear J*. 2024;32(10):338–45. <https://doi.org/10.1007/s12471-024-01896-2>
- 2 Angheloiu GO, Gugiu GB, Ruse C, Pandey R, Dasari RR, Whatling C. Ticagrelor removal from human blood. *JACC Basic Transl Sci*. 2017;2:135–45. <https://doi.org/10.1016/j.jacbs.2017.01.007>
- 3 Hassan K, Geidel S, Zamvar V, Tanaka K, Knezevic-Woods Z, Wendt D, et al. Intra-operative ticagrelor removal via hemoadsorption during on-pump coronary artery bypass grafting. *JTCVS Open*. 2023;15:190–6. <https://doi.org/10.1016/j.xjon.2023.04.013>
- 4 Mair H, Ulrich S, Rosenzweig D, Goepl J, Jurma C, Vogt F, et al. Antithrombotic drug removal with hemoadsorption during off-pump coronary artery bypass grafting. *J Cardiothorac Surg*. 2024;19(1):246. <https://doi.org/10.1186/s13019-024-02772-1>
- 5 Dobesh PP, Oestreich JH. Ticagrelor: pharmacokinetics, pharmacodynamics, clinical efficacy, and safety. *Pharmacother J Hum Pharmacol Drug Ther*. 2014;34(10):1077–90. <https://doi.org/10.1002/phar.1477>
- 6 Furukawa T, Lankadeva Y, Bellomo R. The impact of hemoadsorption on antimicrobials. *J Transl Crit Care Med*. 2024;6(3). <https://doi.org/10.1097/jtccm-d-24-00011>
- 7 Pomarè Montin D, Ankawi G, Lorenzin A, Neri M, Caprara C, Ronco C. Biocompatibility and cytotoxic evaluation of new sorbent cartridges for blood hemoperfusion. *Blood Purif*. 2018;46(3):187–95. <https://doi.org/10.1159/000489921>
- 8 Li A, Li W, Hao F, Wang H. Early stage blood purification for paraquat poisoning: a multicenter retrospective study. *Blood Purif*. 2016;42(2):93–9. <https://doi.org/10.1159/000445991>
- 9 Dong H, Weng Y-B, Zhen G-S, Li F-J, Jin A-C, Liu J. Clinical emergency treatment of 68 critical patients with severe organophosphorus poisoning and prognosis analysis after rescue. *Medicine*. 2017;96(25):e7237. <https://doi.org/10.1097/MD.0000000000007237>
- 10 Yang X, Xin S, Zhang Y, Li T. Early hemoperfusion for emergency treatment of carbamazepine poisoning. *Am J Emerg Med*. 2018;36(6):926–30. <https://doi.org/10.1016/j.ajem.2017.10.048>

Conflict of Interest Statement

Rinaldo Bellomo has received payment from Jafron Biomedical as a member of the Medical Advisory Board and consultancy fees as speaker at several meetings. Rinaldo Bellomo, Ian Baldwin, and Antoine Schneider were all members of the journal's Editorial Board at the time of submission.

Funding Sources

This study was supported by Jafron Biomedical, Zhuhai, China. T.F. was supported by a postgraduate scholarship from the University of Melbourne and Yoshida Foundation Scholarship. Y.R.L. was supported by a Future Leader Fellowship (Level 2) from the National Heart Foundation of Australia [NHF105666] and an Emerging Leader (Level 2) Investigator grant from the National Health and Medical Research Council of Australia [GNT2025266].

Author Contributions

T.F., Y.R.L., I.B., C.P.C.O., C.N.M., and R.B. conceived and designed the research. T.F., I.B., and S.H. performed the experiments. Y.D., A.S., and L.A.D. supervised pharmacological analyses. T.F. analyzed data. T.F., Y.R.L., and R.B. interpreted the data. T.F. drafted the manuscript. All authors edited and revised the manuscript and approved the final version.

Data Availability Statement

The data supporting the findings of this study are not publicly available due to ethical considerations. However, they are available by the corresponding author (R.B.) upon reasonable request.

- 11 Omar S, Sooka PN, Khoza S, Van Rooyen MC, Mashamba L, Madi S, et al. Hemoperfusion for clinically suspected organophosphate and carbamate poisoning in critically ill patients: a randomized trial. *Blood Purif.* 2023;52(2):157–65. <https://doi.org/10.1159/000525936>
- 12 Furukawa T, Lankadeva Y, Baldwin IC, Ow PCC, Hood S, May C, et al. Vancomycin and gentamicin removal with the ha380 cartridge during experimental hemoabsorption. *Blood Purif.* 2023;52(11–12):880–7. <https://doi.org/10.1159/000534108>
- 13 Marsousi N, Rudaz S, Desmeules JA, Daali Y. Liquid chromatography-tandem mass spectrometry method for ticagrelor and its active metabolite determination in human plasma: application to a pharmacokinetic study. *Curr Anal Chem.* 2020;16(5):602–8. <https://doi.org/10.2174/1573411015666190220144904>
- 14 Lorenzin A, de Cal M, Marcello M, Sorbo D, Copelli S, Ronco C, et al. Vancomycin adsorption during in vitro model of hemoperfusion with mini-module of HA380 cartridge. *Blood Purif.* 2023;52(2):174–82. <https://doi.org/10.1159/000526149>
- 15 Schmoedel M, Thielmann M, Hassan K, Geidel S, Schmitto J, Meyer AL, et al. Intraoperative haemoabsorption for antithrombotic drug removal during cardiac surgery: initial report of the international safe and timely antithrombotic removal (STAR) registry. *J Thromb Thrombolysis.* 2024;57(6):888–97. <https://doi.org/10.1007/s11239-024-02996-x>
- 16 Gibson CM, Mack MJ, Lee VT, Schneider DJ, Sellke FW, Ohman EM, et al. Rationale and design of the safe and timely antithrombotic removal - ticagrelor (STAR-T) trial: a prospective, multi-center, double-blind, randomized controlled trial evaluating reductions in postoperative bleeding with intraoperative removal of ticagrelor by the drugsorb™-ATR device in patients undergoing cardiothoracic surgery within 48 hours from last ticagrelor dose. *Am Hear J.* 2022; 245:19–28. <https://doi.org/10.1016/j.ahj.2021.10.188>
- 17 Kietaiabl S, Ahmed A, Afshari A, Albaladejo P, Aldecoa C, Barauskas G, et al. Management of severe peri-operative bleeding: guidelines from the European society of anaesthesiology and intensive Care: second update 2022. *Eur J Anaesthesiol.* 2023;40(4):226–304. <https://doi.org/10.1097/EJA.0000000000001803>
- 18 National Center for Biotechnology Information. PubChem compound summary for CID 14969, vancomycin. 2024. Retrieved November 1, 2024 from: <https://pubchem.ncbi.nlm.nih.gov/compound/Vancomycin>
- 19 National Center for Biotechnology Information. PubChem compound summary for CID 3467, gentamicin. 2024. Retrieved November 1, 2024 from: <https://pubchem.ncbi.nlm.nih.gov/compound/Gentamicin>
- 20 Schneider AG, André P, Scheier J, Schmidt M, Ziervogel H, Buclin T, et al. Pharmacokinetics of anti-infective agents during CytoSorb hemoabsorption. *Sci Rep.* 2021;11(1):10493. <https://doi.org/10.1038/s41598-021-89965-z>